Takeda renews partnership with Structural Genomics Consortium at MaRS Toronto with new investment of $7.5 million

Takeda Pharmaceutical Company Limited (Takeda) today announced it has renewed its partnership with the Structural Genomics Consortium (SGC) to fund collective drug research aimed at bringing new, more effective medicines to patients faster. Takeda has invested an additional CAD$7.5 million, adding to its initial investment in 2012 of CAD$5 million.

Read more

glqxz9283 sfy39587stf02 mnesdcuix8